Oxford, U.K. April 29, 2024 – Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announces that Dr. Per Lundin, Co-Founder and Chief Business Officer, has been appointed as Chief Executive Officer (CEO) of the Company and will be appointed to its Board of Directors. Following more than six years with the … Read more
Novel scaffold proteins for improved drug loading published by Evox co-founder Oxford, UK, August 9, 2023 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced the publication in Nature Communications of Evox-funded research identifying novel exosome scaffold proteins that significantly improve drug loading into exosomes for therapeutic purposes. The publication can be … Read more
The agreement aims to tackle long-standing challenges in cardiovascular disease Oxford, UK, August 4, 2023 – Evox Therapeutics Ltd (‘Evox’), a leading exosome therapeutics company, today announced a research collaboration and option agreement with the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai) in New York, NY. The collaboration will work on developing … Read more
IP bolsters Company’s already dominant and broad position with respect to exosome therapeutics Acquisition is in line with long-term strategy to improve exosome-mediated delivery to enable novel gene therapies and gene editors Oxford, U.K. June 20, 2023 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, has purchased Codiak Biosciences engEx-AAV™ … Read more
Newly issued US patent covers key step in the exosome manufacturing process Oxford, United Kingdom, May 17, 2023 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announced that the Company has been granted another US patent adding to its growing manufacturing IP portfolio. Evox has been granted US Patent … Read more
Six Upcoming Presentations at the Annual Meetings of the American Society of Gene and Cell Therapy (ASGCT) and of the International Society for Extracellular Vesicles (ISEV) OXFORD, United Kingdom, May 12, 2023 (GLOBE NEWSWIRE) — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, will present data at two upcoming international conferences: … Read more
Evox announced that the Company has been granted four newly issued patents covering key purification processes and methods of exogenous loading
Evox announced advances in exosome engineering, manufacturing and tissue targeting at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France.
Evox announced that the company will participate in the 2022 Jefferies Healthcare Conference, to be held on June 8-10, 2022.
OXFORD, United Kingdom, May 19, 2022 — Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, announced titles of nine abstracts to be presented as oral presentations and posters at the International Society for Extracellular Vesicles (ISEV) Annual Meeting, on May 25 to 29, 2022, in Lyon, France. The oral presentations and … Read more